Targeted and tailored therapy in hemato-oncology: vision for the 21st century.
Summarizing our vision of hemato-oncology in the 21st century, we believe that with time, and with the expected progress in both medicine and biotechnology, the role of non-specific chemotherapy will decrease, while that of targeted therapies will increase. Unfortunately, for most tumors chemotherapy is still the cornerstone of treatment. We should therefore focus on finding more targeted agents, better tailoring of treatments, and identifying the risk factors for cancer development and the means of prevention of--what is likely to be--the number one killer of this century.
Shpilberg
Ofer
O
Institute of Hematology, Rabin Medical Center (Beilinson Campus), Petah Tiqva, Israel. ofers2@clalit.org.il
Ben-Bassat
Isaac
I
Raanani
Pia
P
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001709:Biotechnology / Q000639:trends*; D016503:Drug Delivery Systems / Q000639:trends*; D005544:Forecasting; D019337:Hematologic Neoplasms / Q000188:drug therapy* / Q000628:therapy; D006801:Humans; D008495:Medical Oncology / Q000639:trends*; D018570:Risk Assessment; D012307:Risk Factors
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents